台灣臨床試驗主持人資料庫|TPIDB

2017-01-20 - 2025-08-15

Phase III

A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)

Condition/Disease

Locally Advanced Head and Neck Squamous Cell Carcinoma
Test Drug

Keytruda

Participate Sites
10Sites

Terminated10Sites

楊慕華

Taipei Veterans General Hospital

Division of Radiation Therapy

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-04-01 - 2023-12-31

Phase III

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Condition/Disease

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-07-26 - 2020-06-30

Phase III

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

Condition/Disease

Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

Condition/Disease

Triple-Negative Breast Cancer
Test Drug

Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2015-03-01 - 2019-04-30

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Condition/Disease

with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates
Test Drug

SGI-110 for subcutaneous injection

Participate Sites
7Sites

Terminated5Sites

高志平

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Condition/Disease

Acute Myeloid Leukemia (AML)
Test Drug

Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材

Taipei Veterans General Hospital

2017-12-08 - 2023-02-01

Phase III

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

Condition/Disease

Type 2 Diabetes Mellitus in Pediatric Patients
Test Drug

Dapagliflozin / Saxagliptin

Participate Sites
3Sites

Recruiting2Sites

Suspended1Sites

牛道明

Taipei Veterans General Hospital

2017-02-28 - 2020-02-11

Phase II

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-01-06 - 2018-12-31

Phase II

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-08-09 - 2022-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis

Condition/Disease

Secondary Hyperparathyroidism
Test Drug

KHK7580

Participate Sites
10Sites

Terminated10Sites

唐德成

Taipei Veterans General Hospital

Division of Nephrology

Search Result

List